Lv5
1113 积分 2020-11-05 加入
Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation
3天前
已完结
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
3天前
已完结
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
3天前
已完结
Efficacy and safety of iguratimod in patients with primary Sjögren’s syndrome: a multicentre randomised controlled trial
5天前
已完结
Efficacy and safety of iguratimod in patients with primary Sjögren’s syndrome: a multicentre randomised controlled trial
5天前
已完结
Rituximab for Treatment of Advanced Extranodal Marginal Zone B Cell Lymphoma of the Mucosa-Associated Lymphoid Tissue Lymphoma
5天前
已完结
Correction to Lancet Rheumatol 2021; 3: e789–97
7天前
已关闭
Abatacept no better than placebo for pSS
7天前
已完结
Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sjögren’s syndrome: a randomized, phase 2, double-blind, placebo-controlled study
7天前
已完结
CD40 ligand antagonist dazodalibep in Sjögren’s disease: a randomized, double-blinded, placebo-controlled, phase 2 trial
7天前
已完结
皖公网安备34019202002308
